A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Completed · Phase 4

Conditions studied: Well-differentiated Pancreatic Neuroendocrine Tumor

In brief

The purpose of this study is to confirm the safety and efficacy of sunitinib in subjects with unresectable pancreatic neuroendocrine tumors.

Key facts

Study ID

NCT01525550

Run by

Pfizer

People needed

106

Starts

2012-06-06

Expected to finish

2018-07-26

Last updated by the study team

2019-07-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically proven diagnosis of well-differentiated pancreatic neuroendocrine tumor (according to World Health Organization [WHO 2000] classification).
• Disease progression within 12 months prior to study enrollment.
• Disease that is not amenable to surgery, radiation, or combined modality therapy with curative intent.

You may not qualify if…

• Patients with poorly differentiated pancreatic neuroendocrine tumors (according to WHO 2000 classification).
• Prior treatment with any tyrosine kinase inhibitors, anti vascular endothelial growth factor (VEGF) angiogenesis inhibitors, non VEGF targeted angiogenesis inhibitors, or mammalian target of rapamycin (mTOR) inhibitors.

Where it is running

• Univeristy of California — Orange, California, United States
• Columbia University Medical Center — New York, New York, United States
• Barwon Health - University Hospital Geelong — Geelong, Victoria, Australia
• Cliniques Universitaires Saint-Luc, Gastroenterologie — Brussels, Brussels Gewest, Belgium
• China-Japan Friendship Hospital — Beijing, Beijing Municipality, China
• 307 Hospital of PLA — Beijing, Beijing Municipality, China
• Beijing Cancer Hospital — Beijing, Beijing Municipality, China
• Nanjing Bayi Hospital — Nanjing, Jiangsu, China
• West China Hospital of Sichuan University — Chengdu, Sichuan, China
• Fudan University Shanghai Cancer Center — Shanghai, China
• Zhongshan Hospital Fudan University — Shanghai, China
• Masarykuv onkologicky ustav — Brno, Czechia
• Fakultni poliklinika — Prague, Czechia
• Vseobecna Fakultni Nemocnice v Praze — Prague, Czechia
• Hôpital Beaujon — Clichy, France
• Semmelweis Egyetem/II. Sz. Belgyogyaszati Klinika — Budapest, Hungary
• Tata Memorial Hospital — Mumbai, Maharashtra, India
• IEO Istituto Europeo di Oncologia, IRCCS — Milan, Italy
• Kyushu University Hospital — Fukuoka, Fukuoka, Japan
• National Cancer Center Hospital — Chuo-ku, Tokyo, Japan
• Oslo Universitetssykehus HF, Rikshospitalet — Oslo, Norway
• Centrul de Oncologie Sf. Nectarie — Craiova, Dolj, Romania
• Institutul Clinic Fundeni, Centrul de Gastroenterologie si Hepatologie — Bucharest, Romania
• Narodny Onkologicky ustav — Bratislava, Slovakia
• Wits Clinical Research — Johannesburg, Gauteng, South Africa

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.